-+ 0.00%
-+ 0.00%
-+ 0.00%

Tempest Therapeutics CEO Matthew Angel reports indirect purchase of 231,482 shares for $499,999.12

PUBT·06/23/2026 20:56:54
Listen to the news
Tempest Therapeutics CEO Matthew Angel reports indirect purchase of 231,482 shares for $499,999.12
  • Tempest Therapeutics CEO and President Matthew Angel reported indirect beneficial ownership of 231,482 common shares held by Factor Bioscience.
  • Factor also held Series A warrants for 231,482 shares, exercisable at USD 2.16, subject to stockholder approval.
  • Series B warrants covered another 231,482 shares at USD 2.16, also contingent on stockholder approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-279703), on June 23, 2026, and is solely responsible for the information contained therein.